comparemela.com
Home
Live Updates
Pirtobrutinib Continues to Show Safety, Activity in Covalent BTK Inhibitor–Pretreated R/R MCL : comparemela.com
Pirtobrutinib Continues to Show Safety, Activity in Covalent BTK Inhibitor–Pretreated R/R MCL
Jonathon B. Cohen, MD, MS, expands on updated data from the BRUIN trial of pirtobrutinib in patients with relapsed BTK-exposed mantle cell lymphoma.
Related Keywords
Georgia ,
United States ,
Atlanta ,
Emory University ,
Jonathonb Cohen ,
,
Oncology At Emory University School Of Medicine ,
Lymphoma Program ,
Department Of Hematology ,
Safety Monitoring Committee ,
Winship Cancer Institute ,
Medical Oncology ,
Emory University School ,
Pirtobrutinib ,
Mantle Cell Lymphoma ,
Cmcl ,
comparemela.com © 2020. All Rights Reserved.